Evidence map›Paper›PMID 32363580›Full record

ArticleInternational journal of cancer2020

Association of HPV35 with cervical carcinogenesis among women of African ancestry: Evidence of viral-host interaction with implications for disease intervention.

Maisa Pinheiro, Julia C Gage, Gary M Clifford, Maria Demarco, Li C Cheung, Zigui Chen, Meredith Yeager, Michael Cullen, Joseph F Boland, Xiaojian Chen and 21 more

Open access · bronzeAbstract readMulticenter Study
In one paragraph

Article in International journal of cancer, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 4 pooled it
6.3field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 4 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors at 9 institutions in 3 countries.

Maisa PinheiroDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0002-9112-1179
Julia C GageDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0001-5259-6385
Gary M CliffordInternational Agency for Research on Cancer, Lyon, France.ORCID 0000-0001-7534-333X
Maria DemarcoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Li C CheungDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Zigui ChenDepartment of Microbiology, The Chinese University of Hong Kong, Shatin, Hong Kong.
Meredith YeagerDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Michael CullenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Joseph F BolandDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Xiaojian ChenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Tina Raine-BennettDivision of Research, Kaiser Permanente Northern California, Oakland, California, USA.
Mia SteinbergDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Sara BassDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Brian BefanoInformation Management Services, Calverton, Maryland, USA.
Yanzi XiaoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Vanessa TenetInternational Agency for Research on Cancer, Lyon, France.
Joan WalkerUniversity of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Rosemary ZunaUniversity of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA.
Nancy E PoitrasRegional Laboratory, Kaiser Permanente Northern California, Berkeley, California, USA.
Michael A GoldDepartment of Obstetrics and Gynecology, Vanderbilt University, Nashville, Tennessee, USA.
Terence DunnDepartment of Pathology, The University of Oklahoma Health Science Center, Oklahoma City, Oklahoma, USA.
Kai YuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Bin ZhuDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Laurie BurdettDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Sevilay TuranDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Thomas LoreyDivision of Research, Regional Laboratory and Women's Health Research Institute, Kaiser Permanente Northern California, Oakland, California, USA.
Philip E CastleDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.ORCID 0000-0003-1251-0836
Robert D BurkDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, New York, USA.ORCID 0000-0002-8376-8458
Mark SchiffmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
Lisa MirabelloDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland, USA.
National Institutes of Health · USLeidos (United States) · USKaiser Permanente · USUniversity of Oklahoma Health Sciences Center · USAlbert Einstein College of Medicine · USCentre international de recherche sur le cancer · FRChinese University of Hong Kong · HKInformation Management Services · USVanderbilt University · US

Funding

WORD PROCESSORP30CA013330 · NCI · YESHIVA UNIVERSITY · PI THOMAS E ROHAN · 1985 to 2026
$111.2M
Human Papillomavirus (HPV) Genomics ProjectZIACP010228 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI MIRABELLO, LISA · 2016 to 2025
$9.9M
PERSISTENT HUMAN PAPILLOMAVIRUS IN WOMEN AT RISK FOR CERVIX CANCERU01CA078527 · NCI · YESHIVA UNIVERSITY · PI BURK, ROBERT D · 2003 to 2018
$8.6M
PERSISTENT HPV IN WOMEN AT RISK FOR CERVIX CANCERR01CA078527 · NCI · YESHIVA UNIVERSITY · PI BURK, ROBERT D. · 1998 to 2002
$1.5M
CCR NIH HHS HHSN261200800001CNCI NIH HHS CA78527NCI NIH HHS HHSN261200800001ENCI NIH HHS P30 CA013330NCI NIH HHS R01 CA078527NCI NIH HHS U01 CA078527NIH HHS P30CA013330World Health Organization 001
6 · The paper itself

Abstract

HPV35 has been found in only ∼2% of invasive cervical cancers (ICC) worldwide but up to 10% in Sub-Saharan Africa, warranting further investigation and consideration of impact on preventive strategies. We studied HPV35 and ethnicity, in relation to the known steps in cervical carcinogenesis, using multiple large epidemiologic studies in the U.S. and internationally. Combining five U.S. studies, we measured HPV35 positivity and, in Northern California, observed HPV35 type-specific population prevalence and estimated 5-year risk of developing precancer when HPV35-positive. HPV35 genetic variation was examined for differences in carcinogenicity in 1053 HPV35+ cervical specimens from a U.S. cohort and an international collection. African-American women had more HPV35 (12.1% vs 5.1%, P < .001) and more HPV35-associated precancers (7.4% vs 2.1%, P < .001) compared to other ethnicities. Precancer risks after HPV35 infection did not vary by ethnicity (global P = .52). The HPV35 A2 sublineage showed an increased association with precancer/cancer in African-Americans (OR = 5.6 vs A1, 95% CI = 1.3-24.8) and A2 was more prevalent among ICC in Africa than other world regions (41.9% vs 10.4%, P < .01). Our analyses support a strong link between HPV35 and cervical carcinogenesis in women of African ancestry. Current HPV vaccines cover the majority of cervical precancer/cancer across all ethnic groups; additional analyses are required to determine whether the addition of HPV35 to the already highly effective nine-valent HPV vaccine would provide better protection for women in Africa or of African ancestry.

Indexed as

AdultAfrica South of the SaharaBlack or African AmericanFemaleGenetic VariationHumansMiddle AgedPapillomaviridaePapillomavirus InfectionsPhylogenyPrecancerous ConditionsPrevalenceUnited StatesUterine Cervical DysplasiaUterine Cervical NeoplasmsAfrican ancestry womencervical cancerepidemiologygeneticsHPV35

Identifiers

PMID32363580
PMCPMC11090644
OpenAlexW3021574785

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.